Orthocell Ltd (ASX:OCC, OTC:ORHHF) has posted another record quarter, generating $3 million in revenue for the three months ended September 30, 2025, marking its sixth consecutive quarterly record.
The regenerative medicine company’s result was driven primarily by expanding market penetration of its nerve repair device Remplir™ in Australia and Singapore, with early but growing contributions from the United States.
Momentum building across markets
September quarter revenue rose 9.1% on the June quarter’s previous record of $2.7 million, giving Orthocell a compound quarterly growth rate of 9.5% since product launches in FY23.
Quarterly revenue
The company highlighted that the September quarter result did not yet include material contributions from the US, where adoption is expected to accelerate during the December quarter and into the second half of FY26.
Commercialisation highlights in the US include:
- a distributor network covering more than 25 states and 40% of the population;
- initial surgeries completed across multiple hospitals, with more than 100 surgeons introduced to Remplir™; and
- more than 50 value analysis committee (VAC) applications lodged, with 11 approvals in place and scale adoption beginning.
The company also secured its first Canadian distributor during the quarter, with initial sales expected to commence in the December period and adoption forecast to build steadily into 2026.
Read more: Orthocell secures first Canadian distributor for Remplir™, targeting December quarter sales
Significant upside as US adoption builds
Orthocell managing director Paul Anderson said the milestone reflected strong surgeon engagement in core markets.
“The record revenue result for the September quarter is a particularly pleasing result, given it has largely been achieved from our existing markets in Australia and Singapore. It’s a tangible confirmation that surgeons are growing increasingly comfortable using Remplir in nerve repair procedures,” Anderson said.
“Our US Remplir rollout remains on target with early surgical cases having been successfully undertaken during the quarter. As expected, these cases represented a modest financial contribution in the September quarter, but we see significant upside in our revenue growth potential as US momentum builds and Canada comes online,” he added. “This is the market entry plan we followed in Australia and Singapore, and we hope to replicate it on a far larger scale in the US.”
Read more: Orthocell’s Remplir study shows 81% success rate, bolstering US rollout and EU/UK plans
Strong cash position
Orthocell ended the quarter with about $27 million in cash and no debt, providing a strong foundation to continue driving adoption of Remplir™ in the US$1.6 billion American nerve repair market.
The company is also targeting supplementary growth in Canada and other jurisdictions, while maintaining momentum in established markets.
Orthocell said a full Quarterly Activities Report and Appendix 4C would be released by Friday, October 10.